Anti-CTLA-4 immunotherapy does not deplete Foxp3+ cells in human tumours, which suggests that their efficacy could be enhanced by modifying the Fc portions of the mAbs to enhance Fc-mediated depletion of intratumoral Tregs [165]. Here, CTLA4 is linked to neoplasm.